利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.025 秒)

    Compounds as rearranged during transfection (RET) inhibitors
    2.
    发明授权
    Compounds as rearranged during transfection (RET) inhibitors 有权

    公开(公告)号：US10111866B2

    公开(公告)日：2018-10-30

    申请号：US15877524

    申请日：2018-01-23

    申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

    发明人： Michael P. Demartino ,  Huiping Amy Guan

    IPC分类号： A61K31/4439 ,  A61K31/4412 ,  C07D213/69 ,  C07D401/12 ,  C07D413/12

    摘要： This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

    NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS
    5.
    发明申请
    NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS 审中-公开

    公开(公告)号：US20190247382A1

    公开(公告)日：2019-08-15

    申请号：US16376858

    申请日：2019-04-05

    申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

    发明人： Michael P. Demartino ,  Huiping Amy Guan

    IPC分类号： A61K31/4439 ,  A61K31/4412 ,  C07D213/69

    摘要： This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

    Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors
    10.
    发明授权
    Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors 有权

    公开(公告)号：US09918974B2

    公开(公告)日：2018-03-20

    申请号：US15509613

    申请日：2015-09-09

    申请人： GlaxoSmithKline Intellectual Property Development Limited

    发明人： Michael P. Demartino ,  Huiping Amy Guan

    IPC分类号： A61K31/4412 ,  C07D413/12 ,  C07D401/12 ,  C07D213/69 ,  A61K31/4439

    CPC分类号： A61K31/4439 ,  A61K31/4412 ,  C07D213/69 ,  C07D401/12 ,  C07D413/12

    摘要： This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.